Author

Katie A. Link

National Institutes of HealthORCID 0000-0001-7140-2005Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Approach:experimental assay· 1 Organism:mouse· 1

Frequent Co-Authors

Anastas S. PopratiloffiD· 1 shared Cheryl Clarkson ParedesiD· 1 shared Eleni P. HughesiD· 1 shared Ewa KrawczykiD· 1 shared Jay R. KnutsoniD· 1 shared Keely BartoniD· 1 shared Komuraiah MyakalaiD· 1 shared L. Ashley CowartiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Anastas S. PopratiloffORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

The non-steroidal mineralocorticoid receptor (MR) antagonist (FINERENONE) reverses Western diet-induced kidney disease by enhancing mitochondrial metabolism and decreasing lipid accumulation and inflammation

Komuraiah Myakala, Xiaoxin X. Wang, Nataliia V. Shults, Eleni P. Hughes, Patrícia de Carvalho Ribeiro, Rozhin Penjweini, Katie A. Link, Keely Barton, Ewa Krawczyk, Cheryl Clarkson Paredes, Anastas S. Popratiloff, Jay R. Knutson, L. Ashley Cowart, Moshe Levi

This study shows that Finerenone reduces kidney disease in mice by improving mitochondrial function, lowering lipid accumulation, and reducing inflammation.

American Journal of Physiology-Renal Physiology · Sep 29, 2025Peer-reviewedPharmacology & Toxicology